<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33997026</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2314-6141</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2021</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>BioMed research international</Title>
          <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Development of Perphenazine-Loaded Solid Lipid Nanoparticles: Statistical Optimization and Cytotoxicity Studies.</ArticleTitle>
        <Pagination>
          <StartPage>6619195</StartPage>
          <MedlinePgn>6619195</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6619195</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/6619195</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Perphenazine (PPZ), as a typical antipsychotic medical substance, has the same effectiveness compared to atypical antipsychotic medications for the treatment of schizophrenia. Despite the lipophilic essence, PPZ encounters limited bioavailability caused by the first-pass metabolism following oral administration. In the present study, PPZ-containing solid lipid nanoparticles (PPZ-SLNs) were prepared and optimized based on different factors, including lipid and surfactant amount, to develop appropriate and safe novel oral dosage forms of PPZ.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The solvent emulsification-evaporation method was utilized to form SLNs by using soybean lecithin, glycerol monostearate (GMS), and Tween 80. Statistical optimization was done by the Box-Behnken design method to achieve formulation with optimized particle size, entrapment efficiency, and zeta potential. Also, transmission electron microscopy, <i>in vitro</i> release behavior, differential scanning calorimetry (DSC), and powder X-ray diffractometry (P-XRD) studies and cytotoxicity studies were assessed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Optimization exhibited the significant effect of various excipients on SLN characteristics. Our finding indicated that the mean particle size, zeta potential, and entrapment efficiency of optimized PPZ-SLN were, respectively, 104 ± 3.92 nm, -28 ± 2.28 mV, and 83% ± 1.29. Drug release of PPZ-SLN was observed to be greater than 90% for 48 h that emphasized a sustained-release pattern. The DSC and P-XRD studies revealed the amorphous state of PPZ-SLN. FTIR spectra showed no incompatibility between the drug and the lipid. Performing cytotoxicity studies indicated no significant cytotoxicity on HT-29 cell culture.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study suggests that PPZ-SLNs can make a promising vehicle for a suitable therapy of schizophrenia for the oral drug delivery system.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Parisa Abbasi Farsani et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Farsani</LastName>
            <ForeName>Parisa Abbasi</ForeName>
            <Initials>PA</Initials>
            <Identifier Source="ORCID">0000-0002-7709-715X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahjub</LastName>
            <ForeName>Reza</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-7056-2020</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohammadi</LastName>
            <ForeName>Mojdeh</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-3957-2781</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology &amp; Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oliaei</LastName>
            <ForeName>Seyed Sajad</ForeName>
            <Initials>SS</Initials>
            <Identifier Source="ORCID">0000-0002-8654-6148</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants &amp; Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahboobian</LastName>
            <ForeName>Mohammad Mehdi</ForeName>
            <Initials>MM</Initials>
            <Identifier Source="ORCID">0000-0003-1395-1457</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomed Res Int</MedlineTA>
        <NlmUniqueID>101600173</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FTA7XXY4EZ</RegistryNumber>
          <NameOfSubstance UI="D010546">Perphenazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002152" MajorTopicYN="N">Calorimetry, Differential Scanning</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010546" MajorTopicYN="N">Perphenazine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055672" MajorTopicYN="N">Static Electricity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013223" MajorTopicYN="Y">Statistics as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33997026</ArticleId>
        <ArticleId IdType="pmc">PMC8099510</ArticleId>
        <ArticleId IdType="doi">10.1155/2021/6619195</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lieberman J. A., Stroup T. S., Perkins D. O.  Essentials of Schizophrenia. American Psychiatric Pub; 2012. </Citation>
        </Reference>
        <Reference>
          <Citation>Lammer E., Klingelhöfer D., Bendels M., Ohlendorf D., Spallek M., Groneberg D. A. Development of the global schizophrenia research under epidemiological and socio-economic influences. Schizophrenia Research. 2018;199:458–460. doi: 10.1016/j.schres.2018.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.schres.2018.04.001</ArticleId>
            <ArticleId IdType="pubmed">29643010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charlson F. J., Ferrari A. J., Santomauro D. F., et al.  Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia Bulletin. 2018;44(6):1195–1203. doi: 10.1093/schbul/sby058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/schbul/sby058</ArticleId>
            <ArticleId IdType="pmc">PMC6192504</ArticleId>
            <ArticleId IdType="pubmed">29762765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howes O. D., Murray R. M. Schizophrenia: an integrated sociodevelopmental-cognitive model. The Lancet. 2014;383(9929):1677–1687. doi: 10.1016/S0140-6736(13)62036-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)62036-X</ArticleId>
            <ArticleId IdType="pmc">PMC4127444</ArticleId>
            <ArticleId IdType="pubmed">24315522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sendt K.-V., Tracy D. K., Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Research. 2015;225(1-2):14–30. doi: 10.1016/j.psychres.2014.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2014.11.002</ArticleId>
            <ArticleId IdType="pubmed">25466227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Economou A. Sequential-injection analysis (SIA): a useful tool for on-line sample-handling and pre-treatment. TrAC, Trends in Analytical Chemistry. 2005;24(5):416–425. doi: 10.1016/j.trac.2004.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trac.2004.12.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenheck R. A., Leslie D. L., Sindelar J., et al.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry. 2006;163(12):2080–2089. doi: 10.1176/ajp.2006.163.12.2080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2006.163.12.2080</ArticleId>
            <ArticleId IdType="pubmed">17151158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linnet K., Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clinical Pharmacology and Therapeutics. 1996;60(1):41–47. doi: 10.1016/S0009-9236(96)90165-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0009-9236(96)90165-4</ArticleId>
            <ArticleId IdType="pubmed">8689810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong B., Hadinoto K. Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine. Drug Development and Industrial Pharmacy. 2017;43(6):996–1002. doi: 10.1080/03639045.2017.1287721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03639045.2017.1287721</ArticleId>
            <ArticleId IdType="pubmed">28121189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turunen E., Mannila J., Laitinen R., et al.  Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits. The Journal of Pharmacy and Pharmacology. 2011;63(1):19–25. doi: 10.1111/j.2042-7158.2010.01173.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2042-7158.2010.01173.x</ArticleId>
            <ArticleId IdType="pubmed">21155811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laitinen R., Suihko E., Bjorkqvist M., et al.  Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation. Drug Development and Industrial Pharmacy. 2010;36(5):601–613. doi: 10.3109/03639040903386690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/03639040903386690</ArticleId>
            <ArticleId IdType="pubmed">19954406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruni G., Maggi L., Tammaro L., et al.  Electrospun fibers as potential carrier systems for enhanced drug release of perphenazine. International Journal of Pharmaceutics. 2016;511(1):190–197. doi: 10.1016/j.ijpharm.2016.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2016.07.011</ArticleId>
            <ArticleId IdType="pubmed">27418562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baboota S., Mustafa A. G., Sahni J. K., Ali J. Mechanistic approach for the development of ultrafine oil-water emulsions using monoglyceride and blends of medium and long chain triglycerides: enhancement of the solubility and bioavailability of perphenazine. Journal of Excipients and Food Chemicals. 2016;4(1):p. 1099.</Citation>
        </Reference>
        <Reference>
          <Citation>Desai P. P., Date A. A., Patravale V. B. Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. Drug Discovery Today: Technologies. 2012;9(2):e87–e95. doi: 10.1016/j.ddtec.2011.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ddtec.2011.12.001</ArticleId>
            <ArticleId IdType="pubmed">24064268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacciatore I., Ciulla M., Fornasari E., Marinelli L., di Stefano A. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opinion on Drug Delivery. 2016;13(8):1121–1131. doi: 10.1080/17425247.2016.1178237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17425247.2016.1178237</ArticleId>
            <ArticleId IdType="pubmed">27073977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ansari M. J., Anwer M. K., Jamil S., et al.  Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Delivery. 2016;23(6):1972–1979. doi: 10.3109/10717544.2015.1039666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10717544.2015.1039666</ArticleId>
            <ArticleId IdType="pubmed">26017100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur I. P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled Release. 2008;127(2):97–109. doi: 10.1016/j.jconrel.2007.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2007.12.018</ArticleId>
            <ArticleId IdType="pubmed">18313785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darwis Y., Ali Khan A., Mudassir J., Mohtar N. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. International Journal of Nanomedicine. 2013;8:p. 2733. doi: 10.2147/IJN.S41521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S41521</ArticleId>
            <ArticleId IdType="pmc">PMC3732201</ArticleId>
            <ArticleId IdType="pubmed">23926431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahjub R., Heidari Shayesteh T., Radmehr M., et al.  Preparation and optimization of N-trimethyl-O-carboxymethyl chitosan nanoparticles for delivery of low-molecular-weight heparin. Pharmaceutical Development and Technology. 2016;21(1):14–25. doi: 10.3109/10837450.2014.965320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10837450.2014.965320</ArticleId>
            <ArticleId IdType="pubmed">25255172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vafaei S. Y., Dinarvand R., Esmaeili M., Mahjub R., Toliyat T. Controlled-release drug delivery system based on fluocinolone acetonide–cyclodextrin inclusion complex incorporated in multivesicular liposomes. Pharmaceutical Development and Technology. 2015;20(7):775–781. doi: 10.3109/10837450.2014.920358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10837450.2014.920358</ArticleId>
            <ArticleId IdType="pubmed">24856960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gastaldi L., Battaglia L., Peira E., et al.  Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2014;87(3):433–444. doi: 10.1016/j.ejpb.2014.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpb.2014.05.004</ArticleId>
            <ArticleId IdType="pubmed">24833004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahsavari S., Bagheri G., Mahjub R., et al.  Application of artificial neural networks for optimization of preparation of insulin nanoparticles composed of quaternized aromatic derivatives of chitosan. Drug Research. 2014;64(3):151–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24002926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalli R., Bargoni A., Podio V., Muntoni E., Zara G. P., Gasco M. R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. Journal of Pharmaceutical Sciences. 2003;92(5):1085–1094. doi: 10.1002/jps.10368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.10368</ArticleId>
            <ArticleId IdType="pubmed">12712429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gambhirea M., Bhalekarb M., Shrivastavaa B. Bioavailability assessment of simvastatin loaded solid lipid nanoparticles after oral administration. Asian Journal of Pharmaceutical Sciences. 2011;6(6)</Citation>
        </Reference>
        <Reference>
          <Citation>Natarajan J., Baskaran M., Humtsoe L. C., Vadivelan R., Justin A. Enhanced brain targeting efficacy of olanzapine through solid lipid nanoparticles. Artificial Cells, Nanomedicine, and Biotechnology. 2017;45(2):364–371. doi: 10.3109/21691401.2016.1160402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/21691401.2016.1160402</ArticleId>
            <ArticleId IdType="pubmed">27002542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morsi N. M., Ghorab D. M., Badie H. A. Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization. Pharmaceutical Development and Technology. 2013;18(3):736–744. doi: 10.3109/10837450.2012.734513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10837450.2012.734513</ArticleId>
            <ArticleId IdType="pubmed">23477526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H., Chen C.-Y. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Molecular Pharmaceutics. 2013;10(5):1865–1873. doi: 10.1021/mp300649z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp300649z</ArticleId>
            <ArticleId IdType="pubmed">23495754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naseri N., Valizadeh H., Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Advanced Pharmaceutical Bulletin. 2015;5(3):305–313. doi: 10.15171/apb.2015.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15171/apb.2015.043</ArticleId>
            <ArticleId IdType="pmc">PMC4616893</ArticleId>
            <ArticleId IdType="pubmed">26504751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Üner M., Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. International Journal of Nanomedicine. 2007;2(3):289–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676658</ArticleId>
            <ArticleId IdType="pubmed">18019829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verhoeckx K., Cotter P., López-Expósito I., et al.   The Impact of Food Bioactives on Health. Germany: Springer Berlin; 2015. </Citation>
        </Reference>
        <Reference>
          <Citation>Daneshmand S., Golmohammadzadeh S., Jaafari M. R., et al.  Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. Journal of Cellular Biochemistry. 2018;119(6):4251–4264. doi: 10.1002/jcb.26617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.26617</ArticleId>
            <ArticleId IdType="pubmed">29243841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ermer J. Validation in pharmaceutical analysis. Part I: an integrated approach. Journal of Pharmaceutical and Biomedical Analysis. 2001;24(5-6):755–767. doi: 10.1016/S0731-7085(00)00530-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0731-7085(00)00530-6</ArticleId>
            <ArticleId IdType="pubmed">11248468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Andrade D. F., Zuglianello C., Pohlmann A. R., Guterres S. S., Beck R. C. R. Assessing the in vitro drug release from lipid-core nanocapsules: a new strategy combining dialysis sac and a continuous-flow system. AAPS PharmSciTech. 2015;16(6):1409–1417. doi: 10.1208/s12249-015-0330-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-015-0330-0</ArticleId>
            <ArticleId IdType="pmc">PMC4666260</ArticleId>
            <ArticleId IdType="pubmed">25986595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A. K., Wells S. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Transactions on Nanobioscience. 2004;3(1):66–73. doi: 10.1109/TNB.2003.820277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1109/TNB.2003.820277</ArticleId>
            <ArticleId IdType="pubmed">15382647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>des Rieux A., Fievez V., Garinot M., Schneider Y. J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. Journal of Controlled Release. 2006;116(1):1–27. doi: 10.1016/j.jconrel.2006.08.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2006.08.013</ArticleId>
            <ArticleId IdType="pubmed">17050027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy L., Murthy R.  Lymphatic transport of orally administered drugs. Indian Journal of Experimental Biology; 2002. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12693689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary S., Garg T., Murthy R., Rath G., Goyal A. K. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. Journal of Drug Targeting. 2014;22(10):871–882. doi: 10.3109/1061186X.2014.950664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/1061186X.2014.950664</ArticleId>
            <ArticleId IdType="pubmed">25148607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebrahimi H. A., Javadzadeh Y., Hamidi M., Jalali M. B. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU Journal of Pharmaceutical Sciences. 2015;23(1):p. 46. doi: 10.1186/s40199-015-0128-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40199-015-0128-3</ArticleId>
            <ArticleId IdType="pmc">PMC4578325</ArticleId>
            <ArticleId IdType="pubmed">26392174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sznitowska M., Wolska E., Baranska H., Cal K., Pietkiewicz J. The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN) European Journal of Pharmaceutics and Biopharmaceutics. 2017;110:24–30. doi: 10.1016/j.ejpb.2016.10.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpb.2016.10.023</ArticleId>
            <ArticleId IdType="pubmed">27815177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soddu E., Rassu G., Cossu M., Giunchedi P., Cerri G., Gavini E. The effect of formulative parameters on the size and physical stability of SLN based on “green” components. Pharmaceutical Development and Technology. 2016;21(1):98–107. doi: 10.3109/10837450.2014.971376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10837450.2014.971376</ArticleId>
            <ArticleId IdType="pubmed">25331189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kheradmandnia S., Vasheghani-Farahani E., Nosrati M., Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine: Nanotechnology, Biology and Medicine. 2010;6(6):753–759. doi: 10.1016/j.nano.2010.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nano.2010.06.003</ArticleId>
            <ArticleId IdType="pubmed">20599527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews. 2012;64:83–101. doi: 10.1016/j.addr.2012.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2012.09.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pradhan M., Singh D., Singh M. R. Influence of selected variables on fabrication of triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artificial Cells, Nanomedicine, and Biotechnology. 2016;44(1):392–400. doi: 10.3109/21691401.2014.955105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/21691401.2014.955105</ArticleId>
            <ArticleId IdType="pubmed">25229831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah M., Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2 3 full-factorial design. AAPS PharmSciTech. 2010;11(2):489–496. doi: 10.1208/s12249-010-9414-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-010-9414-z</ArticleId>
            <ArticleId IdType="pmc">PMC2902350</ArticleId>
            <ArticleId IdType="pubmed">20309652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam T., Pandit J., Vohora D., Aqil M., Ali A., Sultana Y. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opinion on Drug Delivery. 2015;12(2):181–194. doi: 10.1517/17425247.2014.945416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425247.2014.945416</ArticleId>
            <ArticleId IdType="pubmed">25164097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller R. H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000;50(1):161–177. doi: 10.1016/S0939-6411(00)00087-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0939-6411(00)00087-4</ArticleId>
            <ArticleId IdType="pubmed">10840199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76. doi: 10.1208/s12249-010-9563-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-010-9563-0</ArticleId>
            <ArticleId IdType="pmc">PMC3066374</ArticleId>
            <ArticleId IdType="pubmed">21174180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker Peres L., Becker Peres L., de Araújo P. H. H., Sayer C. Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique. Colloids and Surfaces. B, Biointerfaces. 2016;140:317–323. doi: 10.1016/j.colsurfb.2015.12.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2015.12.033</ArticleId>
            <ArticleId IdType="pubmed">26764112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi A. S., Patel H. S., Belgamwar V. S., Agrawal A., Tekade A. R. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation. Journal of Materials Science. Materials in Medicine. 2012;23(9):2163–2175. doi: 10.1007/s10856-012-4702-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10856-012-4702-7</ArticleId>
            <ArticleId IdType="pubmed">22802103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim S.-J., Kim C.-K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. International Journal of Pharmaceutics. 2002;243(1-2):135–146. doi: 10.1016/S0378-5173(02)00269-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-5173(02)00269-7</ArticleId>
            <ArticleId IdType="pubmed">12176302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ekambaram P., Sathali A. A. H. Formulation and evaluation of solid lipid nanoparticles of ramipril. Journal of Young Pharmacists. 2011;3(3):216–220. doi: 10.4103/0975-1483.83765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0975-1483.83765</ArticleId>
            <ArticleId IdType="pmc">PMC3159275</ArticleId>
            <ArticleId IdType="pubmed">21897661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavanpatil M. D., Jain P., Chaudhari S., Shear R., Vavia P. R. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. International Journal of Pharmaceutics. 2006;316(1-2):86–92. doi: 10.1016/j.ijpharm.2006.02.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2006.02.038</ArticleId>
            <ArticleId IdType="pubmed">16567072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi T. Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of Pharmaceutical Sciences. 1963;52(12):1145–1149. doi: 10.1002/jps.2600521210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.2600521210</ArticleId>
            <ArticleId IdType="pubmed">14088963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gohel M. C., Panchal M. K., Jogani V. V. Novel mathematical method for quantitative expression of deviation from the Higuchi model. AAPS PharmSciTech. 2000;1(4):43–48. doi: 10.1208/pt010431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/pt010431</ArticleId>
            <ArticleId IdType="pmc">PMC2750455</ArticleId>
            <ArticleId IdType="pubmed">14727896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y., Zhang G., Rao Z., et al.  Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. Archives of Pharmacal Research. 2015;38(7):1325–1335. doi: 10.1007/s12272-014-0539-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12272-014-0539-6</ArticleId>
            <ArticleId IdType="pubmed">25567760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girotra P., Singh S. K. Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management. AAPS PharmSciTech. 2017;18(2):517–528. doi: 10.1208/s12249-016-0532-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-016-0532-0</ArticleId>
            <ArticleId IdType="pubmed">27126007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei L., Yang Y., Shi K., Wu J., Zhao W., Mo J. Preparation and characterization of loperamide-loaded Dynasan 114 solid lipid nanoparticles for increased oral absorption in the treatment of diarrhea. Frontiers in Pharmacology. 2016;7:p. 332. doi: 10.3389/fphar.2016.00332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2016.00332</ArticleId>
            <ArticleId IdType="pmc">PMC5030211</ArticleId>
            <ArticleId IdType="pubmed">27708583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Zhao X., Ma Y., Zhai G. X., Li L. B., Lou H. X. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release. 2009;133(3):238–244. doi: 10.1016/j.jconrel.2008.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2008.10.002</ArticleId>
            <ArticleId IdType="pubmed">18951932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souto E., Wissing S., Barbosa C., Müller R. H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. International Journal of Pharmaceutics. 2004;278(1):71–77. doi: 10.1016/j.ijpharm.2004.02.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2004.02.032</ArticleId>
            <ArticleId IdType="pubmed">15158950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dash S., Murthy P. N., Nath L., Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica. 2010;67(3):217–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20524422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dudhipala N., Janga K. Y. Lipid nanoparticles of zaleplon for improved oral delivery by Box–Behnken design: optimization, in vitro and in vivo evaluation. Drug Development and Industrial Pharmacy. 2017;43(7):1205–1214. doi: 10.1080/03639045.2017.1304957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03639045.2017.1304957</ArticleId>
            <ArticleId IdType="pubmed">28274147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhalekar M., Upadhaya P., Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Applied Nanoscience. 2017;7(1-2):47–57. doi: 10.1007/s13204-017-0547-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13204-017-0547-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinarvand R., Jafarzadeh Kashi T. S., Eskandarion, et al.  Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. International Journal of Nanomedicine. 2012;7:p. 221. doi: 10.2147/IJN.S27709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S27709</ArticleId>
            <ArticleId IdType="pmc">PMC3263414</ArticleId>
            <ArticleId IdType="pubmed">22275837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodiya S., Chavhan S., Korde A., Sawant K. K. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Development and Industrial Pharmacy. 2013;39(5):733–743. doi: 10.3109/03639045.2012.694889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/03639045.2012.694889</ArticleId>
            <ArticleId IdType="pubmed">22690834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nooli M., Chella N., Kulhari H., Shastri N. R., Sistla R. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Development and Industrial Pharmacy. 2017;43(4):611–617. doi: 10.1080/03639045.2016.1275666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03639045.2016.1275666</ArticleId>
            <ArticleId IdType="pubmed">28005442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Zeng F., Zong L. Development of orally disintegrating tablets of perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex. Pharmaceutical Development and Technology. 2013;18(5):1101–1110. doi: 10.3109/10837450.2012.700932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10837450.2012.700932</ArticleId>
            <ArticleId IdType="pubmed">22759202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S., Randhawa J. K. Preparation and characterization of paliperidone loaded solid lipid nanoparticles. Colloids and Surfaces. B, Biointerfaces. 2013;102:562–568. doi: 10.1016/j.colsurfb.2012.08.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2012.08.052</ArticleId>
            <ArticleId IdType="pubmed">23104026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasiri F., Faghfouri L., Hamidi M. Preparation, optimization, andin-vitrocharacterization of α-tocopherol-loaded solid lipid nanoparticles (SLNs) Drug Development and Industrial Pharmacy. 2020;46(1):159–171. doi: 10.1080/03639045.2019.1711388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03639045.2019.1711388</ArticleId>
            <ArticleId IdType="pubmed">31894713</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
